conjugate

Antibody drug conjugates are being developed for a range of cancers.

These include organic semiconductors of various kinds, as well as conjugated polymers for sensing and biomedical applications.

Bit by bit, the antibody-drug conjugate therefore recognizes and destroys all cells of the diseased blood system.

Because the antibody drug conjugate specifically targets the cancer cell, it may be possible to administer a lower inhibitor dose than usual which means it's less toxic for the patient.

A particularly surprising finding was that some of the strongest effectors for targeted protein degradation were E2 conjugating enzymes, instead of E3s.